In regulatory filing, DiaMedica Therapeutics disclosed that its director Richard Pilnik and Chief Business Officer David Wambeke each bought 38.36K shares of common stock on June 23rd in a total transaction size of $150K for each person.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DMAC: